Opioid-Like Effects of the Neurokinin 1 Antagonist Aprepitant in Patients Maintained on and Briefly Withdrawn from Methadone

References

• Bammer G, Dobler-Mikola A, Philip M, Strang J, Uchtenhagen A. The heroin prescribing debate: Integrating science and politics. Science 1999; 284:1277–1278.
   PubMed Web of Science ®Google Scholar
• Epstein JF, Groerer JC. Heroin Abuse in United States. The National Clearing house of Alcohol and Drug Information. 1997; Available at: http://www.oas.samhsa.gov/treatan/treana11.htm Last accessed on February 20, 2011.
   Google Scholar
• United Nations Drug Control Programme (UNDCP). Annual Report Questionnaire. International Narcotics Control Strategy Report(s). Washington: US Department of State, 2001. Available at: http://www.state.gov/p/inl/rls/nrcrpt/2001/c6085.htm. Last accessed on January 26, 201.
   Google Scholar
• United Nations Office for Drug Control, Crime Prevention. Global Illicit Drug Trends. 2002. New York: United Nations. Available at: http://www.unodc.org/pdf/report_2002-06-26_1/report_2002-06-26_1.pdf. Last accessed on January 26, 2011.
   Google Scholar
• United Nations Office on Drugs and Crime (UNODC). Report: Promoting health, security and justice, 2010. New York USA: United Nations, 2010. Available at: http://www.unodc.org/documents/frontpage/UNODC_Annual_Report_2010_LowRes.pdf. Last accessed on January 26, 2011.
   Google Scholar
• DASIS Report. TEDS reports on treatment admissions and treatment discharges. Office of Applied Studies, Substance Abuse and Mental Health Services Administration, 2007. Available at: http://oas.samhsa.gov/TEDS2k7highlights/toc.cfm. Last accessed on June 23, 2011.
   Google Scholar
• Office of Applied Studies. The TEDS Report: Substance Abuse Treatment Admissions Involving Abuse of Pain Relievers: 1998 and 2008. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2009. Available at: http://oas.samhsa.gov/2k10/230/230PainRelvr2k10.cfm Last accessed on March 15, 2012).
   Google Scholar
• Fareed A, Casarella J, Amar R, Vayalapalli S, Drexler K. Benefits of retention in methadone maintenance and chronic medical conditions as risk factors for premature death among older heroin addicts. J Psychiatric Prac 2009; 15(3):227–234.
   PubMed Web of Science ®Google Scholar
• Joseph H, Stancliff S, Langrod. Methadone Maintenance Treatment (MMT): A review of historical and clinical issues. The Mount Sinai Medical Journal 2000; 67(5–6):347–364.
   PubMed Web of Science ®Google Scholar
• Mattick RP, Kimber J, Breen C, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Systematic Reviews 2008; 16:CD002207.
   Google Scholar
• Walsh SL, Preston KL, Stitzer ML, Cone EJ, Bigelow GE. Clinical pharmacology of buprenorphine: Ceiling effects at high doses. Clin Pharmacol Therapeu 1994; 55:569–580.
   PubMed Web of Science ®Google Scholar
• Comer SD, Sullivan MA, Walker EA. Comparison of intravenous buprenorphine and methadone self-administration by recently detoxified heroin-dependent individuals. J Pharmacol Exp Ther 2005; 315:1320–1330.
   PubMed Web of Science ®Google Scholar
• Comer SD, Sullivan MA, Whittington RA, Vosburg SK, Kowalczyk WJ. Abuse liability of prescription opioids compared to heroin in morphine-maintained heroin abusers. Neuropsycho pharmacol 2008; 33:1179–1191.
   PubMed Web of Science ®Google Scholar
• Comer SD, Bickel WK, Yi R, de Wit H, Higgins ST, Wenger GR, Johanson CE, Kreek MJ. Human behavioral pharmacology, past, present, and future: Symposium presented at the 50th annual meeting of the Behavioral Pharmacology Society. Behav Pharmacol 2010; 21:251–277.
   Google Scholar
• National Drug Intelligence Center (NDIC). Methadone Diversion, Abuse, and Misuse: Deaths Increasing at Alarming Rate. 2007. Available at: http://www.justice.gov/ndic/pubs25/25930/index.htm Last accessed on June 20, 2011.
   Google Scholar
• Substance Abuse and Mental Health Services Administration (SAMHSA). National Survey of Substance Abuse Treatment Services. Data on Substance Abuse Treatment Facilities. Rockville MD: US Department of Health and Human Services, DHHS Publication SMA 05–4112, 2009.
   Google Scholar
• Murtra P, Sheasby AM, Hunt SP, De Felipe C. Rewarding effects of opiates are absent in mice lacking the receptor for substance P. Nature 2000; 405:180–183.
   Google Scholar
• Ripley TL, Gadd CA, De Felipe C, Hunt SP, Stephens DN. Lack of self-administration and behavioral sensitization to morphine, but not cocaine, in mice lacking NK1 receptors. Neuropharmacol 2002; 43(8):1258–1268.
   Google Scholar
• Gadd CA, Murtra P, De Felipe C, Hunt SP. Neurokinin-1 receptor-expressing neurons in the amygdala modulate morphine reward and anxiety behaviors in the mouse. J Neurosci 2003; 23:8271–8280.
   PubMed Web of Science ®Google Scholar
• Placenza FM, Fletcher PJ, Vaccarino FJ, Erb S. Effects of central neurokinin-1 receptor antagonism on cocaine- and opiate-induced locomotor activity and self-administration behaviour in rats. Pharmacol Biochem Behav 2006; 84:94–101.
   Google Scholar
• Maldonado R, Girdlestone D, Roques BP. RP 67580, a selective antagonist of neurokinin-1 receptors, modifies some of the naloxone-precipitated morphine withdrawal signs in rats. Neurosci Lett 1993; 156:135–140.
   Google Scholar
• Chahl LA, Johnston PA. Effect of the nonpeptide NK-1 receptor antagonist CP-96,345 on the morphine withdrawal response of guinea-pigs. Reg Peptides 1993; 46:373–375.
   Google Scholar
• Hargreaves R, Ferreira JC, Hughes D, Brands J, Hale J, Mattson B, Mills S. Development of aprepitant, the first neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting. Ann NY Acad Sci 2011; 1222:40–48.
   PubMed Web of Science ®Google Scholar
• Haertzen CA. An Overview of Addiction Research Center Inventory Scales (ARCI): An Appendix and Manual of Scales. Rockville, MD: National Institutes on Drug Abuse, 1974.
   Google Scholar
• Handelsman L, Cochrane KJ, Aronson MJ, Ness R, Rubinstein KJ, Kanof PD. Two new rating scales for opiate withdrawal. Am J Drug Alc Abuse 1987; 13:293–308.
   PubMed Web of Science ®Google Scholar
• SPSS I. SPSS 15.0.0 for windows. Chicago, Illinois, 2006.
   Google Scholar
• Gagnon J, Roth JM, Carroll M, Haycock KA, Plamondon J, Feldman DS, Simpson J. Superanova accessible general linear modeling. Yale J Biol Med 1990; 63:191–192.
   Web of Science ®Google Scholar
• Walsh SL, Heilig MA, Nuzzo PA, Lofwall MR. Effects of the NK(1) antagonist, aprepitant, on response to oral and intranasal oxycodone in prescription opioid abusers. Addic Biol 2012. doi: 10.1111/j.1369-1600.2011.00419.x.
   Google Scholar
• DSM-IV. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. (4th ed.). Washington DC: American Psychiatric Association, 1994.
   Google Scholar
• Walsh SL, Strain EC, Bigelow GE. Evaluation of the effects of lofexidine and clonidine on naloxone-precipitated withdrawal in opioid-dependent humans. Addiction 2003; 98:427–439.
   PubMed Web of Science ®Google Scholar